Nektar Therapeutics (NAS:NKTR)
$ 1.08 -0.1 (-8.47%) Market Cap: 199.22 Mil Enterprise Value: 80.51 Mil PE Ratio: 0 PB Ratio: 4.00 GF Score: 59/100

Nektar Therapeutics at JPMorgan Healthcare Conference Transcript

Jan 13, 2020 / 10:30PM GMT
Release Date Price: $27.4 (+1.78%)
Jessica Macomber Fye
JP Morgan Chase & Co, Research Division - Analyst

Great. Good afternoon, everyone. My name is Jess Fye. I'm one of the biotech analysts at JPMorgan, and we're continuing the 2020 Health Care Conference this afternoon with Nektar.

Just a quick housekeeping note. We're going to do a Q&A session with the management team right after this ends. It's down the hall in the Olympic room. You can follow me down there. But with that, I'll turn it over to the company's President and CEO, Howard Robin.

Howard W. Robin
Nektar Therapeutics - CEO, President & Director

Thank you, Jessica. I'm going to be making some forward-looking statements today.

So if you take a look at the therapeutic areas we're working in in the pipeline, I think if you look around this conference, you would be hard-pressed to find a company our size that has such a diverse and important pipeline in areas of pain, immuno-oncology, immunology and also virology. And I think this says a lot about what we've done over the years with our programs.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot